Sign In
Last checked at 
6 Feb 2026 07:00
TRISTEL plc
("Tristel" or the "Company")
Notice of Interim Results
Analyst and Investor briefing schedule
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it will report its interim results for the six-month period ended 31 December 2025 on Monday 2 March 2026.
Analyst briefing
A briefing open to analysts will take place in London on Monday 2 March 2026 at 11.00am. To register and for more details please contact Walbrook PR on tristel@walbrookpr.com
Investor presentation
Matt Sassone, CEO, and Anna Wasyl, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events which are being held at different times to offer convenient options for those wishing to attend.
Two presentations will take place on Monday 2 March 2026 at the following times, the first will be held online via the Investor Meet Company platform and the second will be held in-person in the City of London, full details below:
1. Investor Meet Company online presentation
Tristel management will provide a live online presentation relating to the interim results via Investor Meet Company at 9.30am. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Tristel plc via:
https://www.investormeetcompany.com/tristel-plc/register-investor
2. In-person investor presentation
Tristel management will provide an in-person presentation relating to the Company's interim results at 4.30pm, which is open to all existing and potential shareholders. The Company welcomes investors from 4.15pm for a 4.30pm start and will be followed by refreshments.
If you would like to attend, please contact Walbrook PR for more details on 020 7933 8780 or email tristel@walbrookpr.com.
The results presentation will be made available on the Company's website on the day of results - https://investors.tristel.com/
For further information please contact:
Tristel plc | Via Walbrook PR | ||
Matt Sassone, Chief Executive Officer | https://investors.tristel.com/ | ||
Anna Wasyl, Chief Financial Officer | |||
Walbrook PR Ltd | Tel: 020 7933 8780 or tristel@walbrookpr.com | ||
Paul McManus / Lianne Applegarth / Anna Dunphy | Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 | ||
Cavendish Capital Markets Ltd | Tel: 020 7220 0500 | ||
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance) | |||
Sunila de Silva (ECM) / Louise Talbot (Sales) | |||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
Follow the stocks
